# EDGAR Filing Document

**Accession Number:** 0001954927
**File Stem:** 0001954927-23-000001
**Filing Date:** 2023-2
**Character Count:** 5762
**Document Hash:** a517ef0e31ac31c8195540d9347704e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001954927-23-000001.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001954927-23-000001

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vitro Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0000793171
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 841012042
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-41585
- **FILM NUMBER:** 23633806

**BUSINESS ADDRESS:**
- **STREET 1:** 4621 TECHNOLOGY DRIVE
- **CITY:** GOLDEN
- **STATE:** CO
- **ZIP:** 80403
- **BUSINESS PHONE:** (720) 859-4120

**MAIL ADDRESS:**
- **STREET 1:** 4621 TECHNOLOGY DRIVE
- **CITY:** GOLDEN
- **STATE:** CO
- **ZIP:** 80403

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VITRO DIAGNOSTICS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LABTEK INC
- **DATE OF NAME CHANGE:** 19870217

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMPERIAL MANAGEMENT INC
- **DATE OF NAME CHANGE:** 19870201
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zamora Jack
- **CENTRAL INDEX KEY:** 0001954927

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**MAIL ADDRESS:**
- **STREET 1:** 3200 CHERRY CREEK DRIVE SOUTH
- **STREET 2:** SUITE 720
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80209

```

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.         )

Vitro Biopharma, Inc.
(Name of Issuer)

Common
(Title of Class of Securities)

928501303
(CUSIP Number)

09/09/22
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
Rule 13d-1(b)
 Rule 13d-1(c)
x Rule 13d-1(d)

CUSIP No. 928501303
1.	Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Jack Zamora, M.D.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b)
	3.	SEC use only
	4.	Citizenship or place of organization:  United States citizen
	5.	Sole Voting Power    0
	6.	Shared Voting Power   37,049,318
	7.	Sole Dispositive Power    37,049,318
	8.	Shared Dispositive Power     0
	9.	Aggregate Amount Beneficially owned by Each Reporting Person    37,049,318
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
	11.	Percent of Class Represented by Amount in Row (9)     31.4%
	12.	Type of Reporting Person (See Instructions)    IN

Item 1
(a)	Name of Issuer:  Vitro Biopharma, Inc
(b)	Address of Issuer?s Principal Executive Offices
4621 Technology Drive, Golden, CO 80403
Item 2
(a)	Name of Person Filing   Jack Zamora, M.D.
(b)	Address of Principal Business Office or,
if none, Residence
c/o Vitro Biopharma, 4621 Technology Drive, Golden, CO 80403
(c)	Citizenship  United States
(d)	Title of Class of Securities  Common
(e)	CUSIP Number  928501303
Item 3
	If this statement is filed pursuant to ??240.13d-1(b) or
	240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	Insurance company as defined
in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	Investment company registered under section 8 of the Investment Company Act
of 1940 (15 U.S.C. 80a-8).
(e)	An investment adviser in accordance with ?240.13d-1(b)(1)(ii)(E).
(f)	An employee benefit plan or endowment fund in accordance with ?240.13d-
1(b)(1)(ii)(F).
(g)	A parent holding company or control person in accordance with ?240.13d-
1(b)(1)(ii)(G).
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit
Insurance Act (12 U.S.C. 1813).
(i)	A church plan that is excluded from the definition of an investment company
under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j)	Group, in accordance with ?240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
	Provide the following information regarding the
	aggregate number and percentage of the class of
	securities of the issuer identified in Item 1.
(a)	Amount beneficially owned:  37,049,318
(b)	Percent of Class:  31.4%
(c)	Number of shares as to which the person has:
(i)	Sole power to vote or to direct the vote   0
(ii)	Shared power to vote or to direct the vote   37,049,318
(iii)	Sole power to dispose or to direct the disposition of   37,049,318
(iv)	Shared power to dispose or to direct the disposition of   0
Item 5.  Ownership of Five Percent or Less of a Class
	If this statement is being filed to report the fact that
      as of the date hereof the reporting person has ceased
      to be the beneficial owner of more than five percent of
      the class of securities, check the following:
Item 6.  Ownership of More than Five Percent on Behalf of Another Person.  Not
applicable
Item 7.  Identification and Classification of the
Subsidiary Which Acquired the Security Being
Reported on By the Parent Holding Company.
Not applicable
Item 8.  Identification and Classification of Members
of the Group.  Not applicable
Item 9.  Notice of Dissolution of Group.  Not applicable
Item 10.  Certification.  Not applicable

SIGNATURE
    After reasonable inquiry and to the best of my
    Knowledge and belief, I certify that the information
    set forth in this statement is true, complete and correct.

	2-14-23
                  Date

	/s/ Jack Zamora, M.D.
                     Signature

      Jack Zamora, M.D.
	       Name

```